| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.06. | Olixir NY teams with Crohn's & Colitis Foundation for 'Spill Your Guts' campaign | ||
| 10.06. | Genentech and Novartis dish up food allergy microdrama series | ||
| 10.06. | Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters | ||
| 10.06. | Teva to lay off 250 at API unit as search for new owner drags on: report | ||
| 10.06. | Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery | ||
| 09.06. | WuXi AppTec lands on Pentagon blacklist, facing Biosecure ban | ||
| 09.06. | Merck, Gilead score in effort to develop the first weekly HIV pill | ||
| 09.06. | As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AstraZeneca and Daiichi rivals | ||
| 09.06. | AstraZeneca reprimanded over LinkedIn likes once again | ||
| 08.06. | ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes | ||
| 08.06. | With ADA in the books, analyst says Lilly is 'widening its lead' in the obesity race | ||
| 08.06. | 'Law & Order' star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness campaign | ||
| 08.06. | ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone | ||
| 08.06. | Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi | ||
| 08.06. | Hikma earmarks $267M to expand pair of Ohio production sites, add 350 jobs | ||
| 05.06. | Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25 | ||
| 05.06. | Behind the headlines of ASCO 2026 | ||
| 04.06. | It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin | ||
| 04.06. | ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta | ||
| 04.06. | Axsome fends off generic competition to narcolepsy med Sunosi until 2040 | ||
| 04.06. | Medline earns FDA warning letter ire for repeated toxic bacteria problems | ||
| 03.06. | A patient-first shift in disease language and communication | ||
| 03.06. | Lilly, Boehringer to slash at least $1B each from planned investments in Germany | ||
| 03.06. | Coffee, racetracks, beaches and more coffee-inside the ASCO 2026 exhibit floor | ||
| 03.06. | Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US |